# OnCo record pd-l1-tc-score (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/pd-l1-tc-score/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "pd-l1-tc-score" ;
  schema:name "PD-L1 TC score (tumour-cell score, SP263 and 28-8)"@en ;
  schema:alternateName "PD-L1 TC"@en, "TC score"@en, "tumor cell score"@en, "tumour cell score"@en, "TC >= 1%"@en, "TC >= 50%"@en, "PD-L1 >= 1% tumor cells"@en, "SP263 TC"@en, "28-8 TC"@en, "TC≥1%"@en, "TC≥50%"@en ;
  schema:description "The TC score is the percentage of tumour cells staining for PD-L1 on the SP263 or 28-8 assays. Atezolizumab uses 1 percent after lung surgery and 50 percent for first-line treatment alone; nivolumab with ipilimumab uses 1 percent in first-line lung cancer."@en ;
  schema:url <https://onco.cc/biomarkers/pd-l1-tc-score/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394> ;
  onco:tag "biomarker", "pd-l1" ;
  onco:related <https://onco.cc/biomarkers/pd-l1-cps/>, <https://onco.cc/biomarkers/pd-l1-tps/>, <https://onco.cc/biomarkers/pd-l1-ic-score/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/ventana-pd-l1-sp263/> ;
  onco:terms <https://onco.cc/terms/pd-l1-testing/>, <https://onco.cc/terms/ihc/> .